Navigation Links
Torchmark Prices Senior Notes Offering
Date:6/25/2009

MCKINNEY, Texas, June 25 /PRNewswire-FirstCall/ -- Torchmark Corporation (NYSE: TMK) announced today that it has priced an offering of $300 million in aggregate principal amount of 9.25% Senior Notes that will mature in 2019. Torchmark expects the offering to close on June 30, 2009, subject to the satisfaction of customary closing conditions. The net proceeds of the offering will be used for the repayment of the $99.45 million in aggregate principal amount of Torchmark's 8.25% Senior Debentures that mature on August 15, 2009, and general corporate purposes.

Wachovia Capital Markets, LLC and SunTrust Robinson Humphrey, Inc. are acting as joint book-running managers for the offering.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the notes or any other securities, nor will there be any sale of the notes or any other securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The notes will be sold pursuant to Torchmark's effective shelf registration statement on file with the Securities and Exchange Commission.

The offering of the notes is being made only by means of a prospectus supplement and accompanying prospectus, copies of which may be obtained from:

    Wachovia Capital Markets, LLC
    c/o Wachovia Customer Information Center
    1525 West W.T. Harris Boulevard
    Charlotte, North Carolina 28262-0675
    Attention: Syndicate Operations
    1-800-326-5897

    SunTrust Robinson Humphrey, Inc.
    303 Peachtree Street, 24th Floor
    Mail Code: GA-ATLANTA-3947
    Atlanta, GA  30308
    Attention: Investment Grade Debt Capital Markets
    1-800-685-4786

Alternatively, the prospectus supplement and accompanying prospectus may be obtained by visiting the SEC's Web site at www.sec.gov.

Torchmark Corporation is a holding company specializing in life and supplemental health insurance for "middle income" Americans marketed through multiple distribution channels including direct response, and exclusive and independent agencies.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS:

This press release contains certain statements that may be deemed to be "forward-looking statements" within the meaning of the federal securities laws. These forward-looking statements reflect management's current expectations, but are not guarantees of future performance. Accordingly, please refer to Torchmark's cautionary statement regarding forward-looking statements and the risks and uncertainties applicable to Torchmark's business that are contained in the Company's Form 10-K for the year ended December 31, 2008, and any subsequent Forms 10-Q or Forms 8-K on file with the Securities and Exchange Commission and on the Company's website at www.torchmarkcorp.com on the Investor Relations page. Torchmark specifically disclaims any obligation to update or revise any forward-looking statement because of new information, future developments or otherwise.


'/>"/>
SOURCE Torchmark Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Torchmark Corporation Announces Change in Domicile State of Insurance Subsidiaries to Nebraska
2. Torchmark Corporation Announces Fourth Quarter 2007 Earnings Release and Conference Call
3. Torchmark Corporation to Present at Merrill Lynch Insurance Investors Conference
4. Torchmark Corporation Reports First Quarter 2008 Results
5. Torchmark Corporation Declares Dividend
6. Torchmark Corporation Declares Dividend
7. Torchmark Corporation Announces Fourth Quarter 2008 Earnings Release and Conference Call
8. Torchmark Corporation to Present at Merrill Lynch Insurance Investors Conference
9. Torchmark Corporation Reports First Quarter 2009 Results
10. Lincare Holdings Inc. Prices $500 Million Convertible Senior Debentures Offering
11. American Association for Homecare Disputes Validity of Internet Power Wheelchair Prices as Basis for Reimbursement of Services in Medicare
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... , ... April 24, 2017 , ... ... they are seeking public support to bring their novel lifesaving device for the ... device packed with medical-grade sensors, specially designed to read a child’s vital signs, ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... expected to be diagnosed globally; approximately 25,000 of them will be malignant.(1) As ... use of this type of healthcare model in the diagnosis and treatment of ...
(Date:4/24/2017)... Montclair, NJ (PRWEB) , ... April 24, 2017 , ... ... International Plaza Hotel, 4200 Jim Walter Blvd, for an educational and exciting 2-day program. ... all of our staff hearing this before they approach patients” about the course entitled ...
(Date:4/24/2017)... ... ... “Learning to Use Your SPIRITUAL COMPASS To Navigate Life Issues”: a guide to ... Navigate Life Issues” is the creation of published author, Rachel Jamerson, writer of 25 ... CONTACT USA, and former member of the American Association of Christian Counselors. Rachel ...
(Date:4/24/2017)... ... April 24, 2017 , ... Anaconda BioMed, a pre-clinical ... for the treatment of Acute Ischemic Stroke (AIS), today announced it has appointed ... product advances towards regulatory and clinical phases. , "This is another important step ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017  Cogentix Medical, Inc. (NASDAQ: CGNT), ... the Urology, Uro/Gyn and Gynecology markets with innovative ... has joined the Company as Senior Vice President, ... position, Mr. Keswani will report directly to ... "Our organization is delighted that Ash has joined ...
(Date:4/20/2017)... Mass. , April 20, 2017  RXi ... developing innovative therapeutics that address significant unmet medical ... data from the Company,s consumer product development program, ... at the Society for Investigative Dermatology (SID) 76 ... to advance and promote the sciences relevant to ...
(Date:4/20/2017)... , April 20, 2017  AbbVie (NYSE: ABBV), ... percent (n=145/146) of chronic hepatitis C virus (HCV) ... or 6 and compensated cirrhosis (Child-Pugh A) achieved ... 12 ) with its investigational, pan-genotypic regimen of ... were seen following 12 weeks of G/P treatment ...
Breaking Medicine Technology: